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ABSTRACT Infections with Corynebacterium striatum have been described in the lit-
erature over the last 2 decades, with the majority being bacteremia, central line in-
fections, and occasionally, endocarditis. In recent years, the frequency of C. striatum
infections appears to be increasing; a factor likely contributing to this is the in-
creased ease and accuracy of the identiﬁcation of Corynebacterium spp., includ-
ing C. striatum, from clinical cultures. The objective of this study was to retrospec-
tively characterize C. striatum isolates recovered from specimens submitted as part
of routine patient care at a 1,250-bed, tertiary-care academic medical center. Mul-
tiple strain types were recovered, as demonstrated by repetitive-sequence-based
PCR. Most of the strains of C. striatum characterized were resistant to antimicro-
bials commonly used to treat Gram-positive organisms, such as penicillin, ceftriax-
one, meropenem, clindamycin, and tetracycline. The MIC50 for ceftaroline was 32
g/ml. Although there are no interpretive criteria for susceptibility with telavancin, it
appeared to have potent in vitro efﬁcacy against this species, with MIC50 and MIC90
values of 0.064 and 0.125 g/ml, respectively. Finally, as previously reported in case
studies, we demonstrated rapid in vitro development of daptomycin resistance in
100% of the isolates tested (n  50), indicating that caution should be exhibited
when using daptomycin for the treatment of C. striatum infections. C. striatum is an
emerging, multidrug-resistant pathogen that can be associated with a variety of in-
fection types.
KEYWORDS Corynebacterium, Corynebacterium striatum, antimicrobial agents,
opportunistic infections, susceptibility testing, telavancin
Recent advances in organism detection and identiﬁcation have facilitated an im-proved understanding of the clinical signiﬁcance of some bacterial species previ-
ously thought to be largely commensal organisms, such as the “coryneform” bacteria.
While the pathogenicity of certain Corynebacterium spp., such as Corynebacterium
diphtheriae, has been well established and described in the literature, non-diphtheriae
Corynebacterium spp. are increasingly being associated with disease in immunocom-
petent and immunocompromised patients. A 2012 case series linked Corynebacterium
spp. to signiﬁcant respiratory disease in 27 patients, whereas a similar 2013 case series
linked Corynebacterium spp. to respiratory disease in 10 patients (1, 2). Interestingly,
while the majority of respiratory infections in each study were caused by the estab-
lished respiratory pathogen Corynebacterium pseudodiphtheriticum, both studies found
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Corynebacterium striatum to be a cause for a large proportion of infections (26% and
20%, respectively).
Several microbiome surveys have established Corynebacterium striatum as a com-
mon component of the skin microbiota (3–6). In addition, infections with Corynebac-
terium striatum have been described in the literature over the last 2 decades. Similar to
other skin ﬂora, the majority of the described infections have been limited to isolated
bacteremia, central line infections, and occasionally, endocarditis (7–16). Over recent
years, the scope of these infections has broadened to include respiratory, wound,
medical hardware/devices, and even urinary tract infections (16–23). While the reasons
for this increased association with multiple pathological processes may not be entirely
apparent, a likely contributing factor is the increased ease and accuracy of the identi-
ﬁcation of Corynebacterium spp., including C. striatum, from clinical cultures (24, 25).
Compared to other Gram-positive skin ﬂora, C. striatum is relatively resistant to
antimicrobial therapy. Effective treatment usually requires aggressive source control
(i.e., heart valve or central line removal) or prolonged therapy with intravenous anti-
biotics with broad Gram-positive activity (10, 11, 13, 14). A recent survey of over 100 C.
striatum isolates derived from various patient specimens in a U.S. hospital over a
10-year period found resistance to many commonly used antimicrobials (23). Vanco-
mycin was found to be the only universally active antibiotic. Isolated case reports have
suggested that infections can be successfully treated with linezolid or daptomycin
(10–13). However, prolonged therapy with linezolid is cost prohibitive and often
complicated by neutropenia and/or drug-drug interactions. While therapy with dapto-
mycin may have a more favorable side effect proﬁle, the failure of prolonged dapto-
mycin therapy has been documented in multiple case reports (16, 22). This failure of
therapy has been attributed to the rapid emergence of isolates with a resistant
phenotype under selective antibiotic pressure (16).
The objective of this study was to retrospectively characterize Corynebacterium
striatum isolates from specimens submitted as part of routine patient care, including
trends in antibiotic resistance. In addition, we sought to characterize the in vitro activity
of telavancin against multidrug-resistant C. striatum.
RESULTS
Epidemiology. C. striatum isolates were reported most commonly in wound and
respiratory specimens from patients ranging from 50 to 69 years of age (Table 1). The
characteristics of patients with C. striatum recovered in clinical specimens did not differ
signiﬁcantly by gender from those recovered in patients with coagulase-negative
staphylococci (CNS) (P  0.95) or Staphylococcus aureus isolates (P  0.95). There was
a signiﬁcantly higher percentage of patients in the 60- to 69-year age range with C.
striatum than with S. aureus (P  0.02). Compared to CNS and S. aureus, C. striatum
isolates were more often isolated from wound specimens, tissue specimens, and bone
specimens (P  0.01). Approximately 46.1% (119/256) of the C. striatum isolates were
from monomicrobial cultures (Table 2). The most common monomicrobial specimen
sources were blood (18%), tracheal aspirates (13%), and tissue (13%). In polymicrobial
cultures, C. striatum was accompanied by normal ﬂora in 55% of the cultures, one other
organism in 27% of the cultures, two other organisms in 10% of the cultures, and three
other organisms in 3% of the cultures. Organisms commonly coisolated with C. striatum
included S. aureus (36/137 [26.3%]), CNS (15/137 [10.9%]), and Pseudomonas aeruginosa
(15/137 [10.9%]). Of the C. striatum isolates recovered from respiratory specimens, 75%
(46/61) were from tracheal aspirates (26% monomicrobial, 49% polymicrobial) (Table 3).
Of the blood isolates, 91% (21/23) were from peripheral draws.
Identiﬁcation. In a comparison of the Bruker Biotyper and the Vitek MS, there was
100% agreement (85/85 isolates) for all isolates tested. Both instruments also had 100%
agreement in identiﬁcation for four isolates previously misclassiﬁed as C. striatum
(Corynebacterium tuberculostearicum, n  1 and Corynebacterium simulans, n  3); all
were previously misclassiﬁed by RapID CB Plus, except for an isolate of C. simulans
misclassiﬁed by Bruker matrix-assisted laser desorption ionization–time of ﬂight mass
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spectrometry (MALDI-TOF MS) analysis at the time of initial culture. In a comparison of
the MALDI-TOF MS results to RapID CB Plus results when available historically (n  43),
it was found that the RapID CB Plus misclassiﬁed three isolates as C. striatum. Of these
isolates, two were C. simulans isolates which had colony morphologies similar to those
of C. striatum, although they had susceptibility proﬁles differing from the typical
C. striatum proﬁle (i.e., the isolate was susceptible to all drugs tested). The other was a
C. tuberculostearicum isolate which had a susceptibility proﬁle similar to the typical C.
striatum proﬁle but had a different colony morphology. In a comparison of these three
organisms morphologically, both C. striatum and C. simulans have large white colonies,
whereas C. tuberculostearicum has small pinpoint colonies (Fig. 1).
Antimicrobial susceptibility testing. Antibiotic susceptibility breakpoints used
were derived from CLSI document M45, 3rd edition (26). For most of the isolates,
susceptibility testing revealed resistance to most of the drugs tested (Table 4). It was
demonstrated that for cefotaxime, ceftriaxone, meropenem, ciproﬂoxacin, tetracycline,
penicillin, and clindamycin, the MIC50 would be classiﬁed as resistant. Interpretive
criteria are not available for ceftaroline, but the MIC50 and MIC90 were both32 g/ml.
For vancomycin, linezolid, and daptomycin, the MIC50 would be classiﬁed as suscepti-
ble. The 87 isolates tested for telavancin susceptibility exhibited an MIC50 of 0.064
g/ml and an MIC90 of 0.125 g/ml.
Development of daptomycin resistance. Upon overnight incubation of 50 isolates
with daptomycin, 100% of the isolates became nonsusceptible to the drug (Table 5).
Interestingly, overnight incubation with daptomycin also had an effect on vancomycin
TABLE 1 Patient characteristics for laboratory-reported C. striatum compared to
Staphylococcus spp. in clinical specimensa
Characteristicb
Corynebacterium
striatum
(n  256)
Coagulase-
negative
Staphylococcus
(n  1,537)
Staphylococcus
aureus (n  2,655)
No. % No. % No. %
Sex
Male 141 55.1 852 55.43 1,469 55.33
Female 115 44.9 685 44.57 1,186 44.67
Age (yr)
20 3 1.2 18 1.17 39 1.47
20–29 15 5.9 123 8.00 345 12.99
30–39 19 7.4 148 9.63 272 10.24
40–49 26 10.2 188 12.23 355 13.37
50–59 65 25.4 326 21.21 533 20.08
60–69 72 28.1 379 24.66 578 21.77
70–79 36 14.1 237 15.42 353 13.30
80–89 16 6.3 97 6.31 160 6.03
90 4 1.6 21 1.37 20 0.75
Source
Wound 67 26.2 180 11.71 449 16.91
Respiratory 61 23.8 3 0.20 455 17.14
Tissue (lymph node) 36 14.1 78 5.07 180 6.78
Bone 30 11.7 22 1.43 37 1.39
Blood 23 9.0 669 43.53 381 14.35
LVAD 7 2.7 5 0.33 7 0.26
Urine 3 1.2 296 19.26 141 5.31
Other, sterilec 14 5.5 211 13.73 348 13.11
Other, nonsteriled 15 5.9 73 4.75 657 24.75
aAll isolates were isolated from clinical samples from 1 January 2013 to 31 December 2015.
bLVAD, left ventricular assist device.
cIncludes aspirate, biopsy, catheter tip, cerebrospinal ﬂuid, hardware, joint ﬂuid, pleural ﬂuid, peritoneal ﬂuid,
shunt, stones, synovial ﬂuid, and valve specimens.
dIncludes cervical, cyst, cornea, drainage, genital, lesion, ocular swab, placenta, sinus, stool, ulcer, urethra,
vaginal, vesicle, and wound specimens.
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and telavancin MICs. The vancomycin MIC50 and MIC90 increased from 0.38 g/ml to
0.50 g/ml and from 0.50 g/ml to 0.75 g/ml, respectively. Following incubation with
daptomycin, the telavancin MIC50 and MIC90 (48-h read) dropped from 0.016 g/ml to
0.012 g/ml and 0.023 g/ml to 0.016 g/ml, respectively.
Molecular typing. For the 85 isolates available for molecular typing, there were 12
strain types detected; each strain type was given an alpha designation. The most
common strain type detected was F, accounting for approximately half of the isolates
(44/85 [52%]). The next most common strain type was D (10/85), and the remaining
isolates were classiﬁed into 10 different strain types (Table 6). All types appeared to be
equally distributed among different specimen sources. There did not appear to be any
major differences between the susceptibility testing results for the different types.
DISCUSSION
Although coryneforms are commonly considered commensals of the skin and
mucosal surfaces, some species are associated with speciﬁc disease manifestations.
Herein, we describe the epidemiology and antimicrobial resistance proﬁles of the
emerging multidrug-resistant pathogen C. striatum.
The commonality of C. striatum in respiratory specimens, particularly monomicrobial
tracheal aspirates, supports previous studies suggesting that C. striatum is an emerging
respiratory pathogen (1, 20, 27). The speciﬁc association with tracheal aspirates may be
TABLE 2Monomicrobial cultures with C. striatum by site
Specimen typea No. (% total cultures)
Blood 22 (18)
Tracheal aspirate 16 (13)
Tissue 15 (13)
Wound 14 (12)
Bone 11 (9)
LVAD 7 (6)
Bronchoalveolar lavage ﬂuid 7 (6)
Synovial ﬂuid 6 (5)
Nonsterile siteb 5 (4)
Peritoneal ﬂuid 3 (3)
Pleural ﬂuid 2 (2)
Abscess 2 (2)
Bronchial washing 1 (1)
Aspirate 1 (1)
Lung tissue (autopsy) 1 (1)
Graft 1 (1)
Urine 1 (1)
Unknown 4 (3)
Total 119
aLVAD, left ventricular assist device.
bIncludes cervical, cyst, cornea, drainage, genital, lesion, ocular swab, placenta, sinus, stool, ulcer, urethra,
vaginal, vesicle, and wound specimens.
TABLE 3 Comparison of monomicrobial and polymicrobial cultures with C. striatum
Culture source
No. of monomicrobial
cultures (% of
specimen type)
No. of polymicrobial
cultures (% of
specimen type) Total (%)
Tracheal aspirate 16 (26) 30 (49) 46 (75)
Bronchoalveolar lavage ﬂuid 7 (11) 4 (7) 11 (18)
Bronchial washing 1 (2) 2 (3) 3 (5)
Sputum 0 (0) 1 (2) 1 (2)
Total from respiratory cultures 24 (39) 37 (61) 61
Peripheral blood draw 20 (87) 1 (4) 21 (91)
Central line blood draw 2 (9) 0 (0) 2 (9)
Total from blood cultures 22 (96) 1 (4) 23
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explained by increased bioﬁlm production allowing the organism to adhere to instru-
ments used for endotracheal intubation, a mechanism explored by Souza et al. (20).
Similar to previous studies, C. striatum was commonly isolated from a variety of other
specimen types, including tissue, wounds, left ventricular assist devices, and blood
cultures. Notably, the majority of positive blood specimens were collected from pe-
ripheral sites rather than central lines, suggesting that while C. striatum can cause
infection of endovascular devices, this is not necessarily the only factor contributing to
bacteremia. In addition, our ﬁndings demonstrate that C. striatum is isolated from
different types of clinical specimens from those of other skin commensals, such as
coagulase-negative Staphylococcus spp., raising the possibility that C. striatum may
have a different predilection for wound, tissue, and bone infections from some other
bacteria that are considered to be a component of normal skin ﬂora.
In a comparison of the identiﬁcation results for C. striatum isolates from two
commercially available MALDI-TOF MS identiﬁcation systems (Bruker MS and Vitek MS),
we observed that the two systems perform similarly for C. striatum identiﬁcation. In
contrast, some misidentiﬁcations were observed using the RapID CB Plus phenotypic
identiﬁcation system. Misidentiﬁcation of C. simulans as C. striatum by the RapID CB Plus
FIG 1 Morphological characteristics of C. tuberculostearicum, C. simulans, and C. striatum. (a) Colony morphology of C.
tuberculostearicum. At 24 h of growth on sheep blood agar, colonies are pinpoint and barely visible. (b) Colony morphology
of C. simulans. At 24 h of growth on sheep blood agar, colonies are large and white. (c) Colony morphology of C. striatum. At
24 h of growth on sheep blood agar, colonies are large and white. (d) Gram stain of C. striatum showing typical coryneform
morphology of palisading Gram-positive bacilli.
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was observed in our investigation, and this has also been described previously (28). This
is perhaps not surprising, since these two organisms share 98% 16S rRNA gene
sequence homology and biochemically are very similar. In fact, the species name
“simulans” is derived from the fact that this organism is “similar” to C. striatum. However,
based on the two C. simulans isolates included in our study, these similarities do
not extend to antibiotic resistance proﬁles. In sharp contrast to the broad antibiotic
resistance seen in C. striatum, both C. simulans isolates included in this study were
susceptible to all antibiotics tested. Although the antibiotic susceptibility pattern of C.
simulans has not been well characterized in the literature, Cazanave et al. previously
described a C. simulans prosthetic joint isolate that was susceptible to penicillin and
vancomycin (29). Our ﬁndings suggest that laboratories relying on phenotypic identi-
ﬁcation methods should consider possible misidentiﬁcation when a C. striatum isolate
is found to be broadly susceptible to antimicrobial agents and seek an alternative
identiﬁcation method. Although the misidentiﬁcation of C. tuberculostearicum as C.
striatum by the RapID CB Plus has not been speciﬁcally described, a high rate of
misidentiﬁcation of C. tuberculostearicum, as with other Corynebacterium spp., has been
shown by other investigators (30). Misidentiﬁcations of C. striatum as C. tuberculoste-
aricum can be avoided by careful attention to the colony morphology, which should be
large for C. striatum (nonlipophilic) and small for C. tuberculostearicum (lipophilic) (30).
Our ﬁndings describing the resistance of C. striatum to many of the commonly used
antibiotics with Gram-positive activity are consistent with other recent surveys of C.
striatum resistance (23, 31). Several recent studies have explored the efﬁcacy of
ceftaroline for uncommonly isolated Gram-positive organisms, including C. striatum (32,
33). Sader et al. examined the efﬁcacy of ceftaroline in 19 Corynebacterium sp. isolated
clinical specimens obtained from 2008 to 2011, of which eight were identiﬁed as C.
striatum (32). The study found varied efﬁcacy of ceftaroline (MIC50, 0.5 g/ml; MIC90,
32 g/ml) among the Corynebacterium spp., although the investigators did not
TABLE 4 Antimicrobial susceptibility proﬁles of C. striatum isolates
Antimicrobial
tested
No. of isolates
tested % susceptiblea
MIC data (g/ml)
MIC50 MIC90 Range
Penicillin 43 16 8 32 0.25 to 256
Cefotaxime 16 0 256 256 256
Ceftriaxone 124 1 256 256 0.25 to 256
Ceftaroline 87 NA 32 32 0.25 to 32
Meropenem 87 4 32 32 0.125 to 32
Vancomycin 207 100 1 2 0.5 to 2.0
Daptomycin 91 98 0.125 0.25 0.032 to 256
Telavancin 87 NA 0.064 0.125 0.008 to 0.125
Tetracycline 206 38 64 256 0.064 to 256
Ciproﬂoxacin 203 7 32 32 0.032 to 32
Clindamycin 140 1 256 256 0.064 to 256
Linezolid 120 100 0.50 0.50 0.125 to 2.0
aBased on CLSI M45, 3rd edition (26). NA, no interpretative data available.
TABLE 5 Effects of 24-h daptomycin exposure on isolate susceptibility
Drug tested
Incubation with
daptomycin
MIC50/MIC90 (g/ml)a No. susceptible/
total no. (%)b
No. nonsusceptible/
total no. (%)bMIC50 at 24 h MIC90 at 24 h MIC50 at 48 h MIC90 at 48 h
Daptomycin Preincubation 0.094 0.125 NP NP 48/50 (96) 2/50 (4)
Postincubation 256 256 NP NP 0/50 (0) 50/50 (100)
Vancomycin Preincubation 0.25 0.38 0.38 0.50 50/50 (100) 0/50 (0)
Postincubation 0.38 0.50 0.50 0.75 50/50 (100) 0/50 (0)
Telavancin Preincubation 0.012 0.016 0.016 0.023 NA NA
Postincubation 0.012 0.016 0.012 0.016 NA NA
aNP, not performed.
bBased on CLSI M45, 3rd edition (26). NA, no interpretative data available.
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speciﬁcally report the susceptibility results for C. striatum. Another study published in
2013 by Goldstein et al. had similar results (33). Goldstein et al. examined ceftaroline
efﬁcacy in organisms isolated from diabetic foot wounds from the previous 11 years.
Similar to Sader et al., these authors tested 36 Corynebacterium spp., of which 10 were
identiﬁed as C. striatum and demonstrated varied activity against ceftaroline among
Corynebacterium spp. (MIC50, 0.125 g/ml; MIC90, 2 g/ml), although they did not
speciﬁcally report the activity in C. striatum isolates. Our ﬁndings of nearly universal
resistance to ceftaroline by C. striatum speciﬁcally may account for the varied resistance
observed when mixed populations of Corynebacterium spp. are tested for resistance.
Our ﬁndings suggest that for C. striatum infection, ceftaroline is unlikely to be a viable
therapeutic option. We hypothesize that this resistance is due to the modiﬁcation of
penicillin-binding proteins.
Our study is the ﬁrst to measure in vitro telavancin activity against a large collection
of C. striatum strains. While interpretive criteria do not exist for telavancin and C.
striatum, an MIC90 of 0.125 g/ml would be interpreted as susceptible for Staphylo-
coccus species (34). Although additional studies are needed to substantiate the rela-
tionship between in vitro susceptibly data and clinical response, telavancin may rep-
resent a viable therapeutic option for infection with C. striatum.
The rapid emergence of daptomycin resistance is an established phenomenon for
some strains of C. striatum; a previous publication demonstrated this phenomenon in
approximately 58% (7/12) of susceptible C. striatum isolates (16). In our study, we found
that 100% (48/48) of susceptible C. striatum isolates exhibited this phenotype, demon-
strating that the development of daptomycin resistance is common. Furthermore,
previous studies have shown that this is a stable phenotype and that these isolates can
remain resistant to daptomycin following at least 10 serial passages (16). Overall, these
data suggest that caution should be taken when using this drug for the treatment of
C. striatum infections, even for those isolates that initially exhibit in vitro susceptibility.
Although subtle, and possibly within the margin of error for MIC testing, the phenotype
of elevation in vancomycin MICs following incubation with daptomycin is intriguing
and has not been previously described for C. striatum. However, a similar phenomenon
has been described when Staphylococcus aureus isolates are exposed to vancomycin,
resulting in a phenotype with cell wall thickening and in an elevated MIC for both
vancomycin and daptomycin (35). Interestingly, we observed an opposite effect for
telavancin.
Several published studies have suggested that the presence of multidrug-resistant
C. striatum in the environment is the result of clonal spread of a speciﬁc strain. A 2009
case series from Italy examined 36 strains isolated from three hospitals over a 3-year
period (9). Using pulsed-ﬁeld gel electrophoresis, this group demonstrated that all
isolates were from a single clone containing several genes conferring antibiotic resis-
tance. A second 2013 study performed in Brazil examined 15 separate C. striatum
TABLE 6 Distribution of repetitive-sequence PCR types of C. striatum isolates
REP-PCR
type (n)a
No. (%) of
monomicrobial isolates Blood Bone Pleural ﬂuid Graft Joint LVADb Tissue Wound Unknown
F (44) 31 (70) 15 12 1 0 4 3 5 4 0
D (10) 5 (50) 1 2 0 0 1 1 4 1 0
I (6) 1 (17) 0 1 0 0 1 0 4 0 0
A (5) 3 (60) 1 2 0 0 0 0 1 0 1
H (4) 2 (50) 1 3 0 0 0 0 0 0 0
J (4) 3 (75) 1 1 1 0 0 0 1 0 0
C (5) 4 (80) 0 1 0 1 3 0 0 0 0
K (3) 2 (66) 0 1 0 0 0 1 0 1 0
B (1) 1 (100) 1 0 0 0 0 0 0 0 0
E (1) 0 (0) 0 0 0 0 0 0 0 1 0
G (1) 0 (0) 0 0 0 1 0 0 0 0 0
L (1) 1 (100) 1 0 0 0 0 0 0 0 0
aREP-PCR, repetitive-sequence PCR.
bLVAD, left ventricular assist device.
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isolates isolated from tracheal aspirates for clonality (27). Using pulsed-ﬁeld gel elec-
trophoresis, this group showed that most multidrug-resistant isolates were related to a
single clone, which may have spread due to an enhanced ability to create bioﬁlms (20).
The ﬁndings differ from those of our current study, which describe the epidemiology of
C. striatum infection in a nonoutbreak setting. Although a dominant strain type was
detected, nearly half (41/85 [48%]) of the isolates were distributed among 12 other
strain types. The resistance phenotype was not unique to the dominant clone, as the
majority of C. striatum isolates included in the analysis were multidrug resistant.
Furthermore, clonality did not appear to account for any trends in type of infection or
resistance proﬁle to any speciﬁc antimicrobial agent.
Strengths of our study are its size and temporal span, facilitating the interrogation
of epidemiology and antimicrobial resistance proﬁles. Additional strengths are the
availability of comprehensive susceptibility testing data and the assessment of the
potential for the development of daptomycin resistance among a large sampling of
isolates. Finally, our strain typing data illustrated that these ﬁndings are not driven by
an expansion of a single clone and thus may represent the characteristics of C. striatum
in general. Our study is limited by the fact that it is a retrospective, single-center study;
thus, the results may not be generalizable to other settings. Furthermore, while the
included C. striatum isolates were reported based on site and organism predominance,
their presence does not necessarily conﬁrm pathogenicity. Finally, MIC determination
was performed using only one method. Conﬁrmation of results, especially shifts in
vancomycin MICs after daptomycin exposure with a second method, would strengthen
this study.
In summary, our data support the characterization of C. striatum as an emerging
multidrug-resistant pathogen. Vancomycin, linezolid, and telavancin demonstrate good
in vitro activity against the organism, while resistance to penicillin, cephalosporins,
ciproﬂoxacin, meropenem, tetracycline, and clindamycin is common.
MATERIALS AND METHODS
Study overview. Following institutional review board (IRB) approval, we performed a retrospective
review of 256 C. striatum isolates recovered from a variety of clinical specimens submitted to the
microbiology laboratory of Barnes-Jewish Hospital, a 1,250-bed, tertiary-care hospital, from 2012 to 2015.
All isolates were identiﬁed and reported as a part of routine patient care based on specimen source and
abundance. Speciﬁcally, C. striatum was only reported in polymicrobial cultures when there was evidence
that it was a potential pathogen (predominant organism grown, coryneforms observed in the direct
specimen Gram stain, present with polymorphonuclear leukocytes, positive in multiple blood culture
sets, etc.). The following information was obtained for each isolate: specimen type, presence of other
microorganisms, identiﬁcation methodology, and results of any susceptibility testing performed. A chart
review of each corresponding patient was performed in order to obtain gender and age. For comparison,
the same review was performed for CNS and Staphylococcus aureus isolates obtained during the same
time period.
Identiﬁcation. C. striatum isolates were originally identiﬁed either by RapID CB Plus (Remel, Lenexa,
KS) or MALDI-TOF MS (Bruker Biotyper, Bruker Daltonics, Inc., Billerica, MA), as per the standard operating
procedures at the time of isolation. These identiﬁcations were retrospectively retrieved by chart review
at the time of the study. A subset of these isolates that had been stored at 70°C was further
characterized for the purposes of the study. The identiﬁcation of these frozen isolates was conﬁrmed
using both the Vitek MS IVD version 2.3.3 (bioMérieux, Durham, NC) and the Bruker Biotyper version 5.
The percent agreement between the methods used was obtained.
Antimicrobial susceptibility testing. For the all isolates included in the study, susceptibility testing
was initially performed when deemed clinically appropriate as a part of routine patient care using
gradient diffusion Etest (bioMérieux, Durham, NC). The subset of frozen isolates that were further
characterized received additional susceptibility testing evaluating meropenem, ceftaroline, linezolid,
telavancin, and daptomycin using gradient diffusion (Etest) on Mueller-Hinton agar with sheep blood.
The results were read at 24 and 48 h and interpreted using CLSI interpretative breakpoints (CLSI
document M45, 2nd and 3rd editions) (26, 36).
Development of daptomycin resistance. To further characterize the ability of C. striatum to develop
resistance to daptomycin, 50 daptomycin-susceptible isolates were incubated overnight with daptomy-
cin Etests, as per a previously published protocol (16). In brief, each isolate was inoculated into two 5-ml
tubes of tryptic soy broth at an optical density of a 0.5 McFarland standard. A daptomycin Etest was cut
in half, and both halves of the Etest were submerged into one tube, whereas the other tube served as
the growth control. Tubes were incubated at 35°C room air under constant agitation overnight. Isolates
that were turbid after incubation were tested for MICs to daptomycin, vancomycin, and telavancin using
McMullen et al. Antimicrobial Agents and Chemotherapy
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gradient diffusion (Etest) assays. The MIC50 and MIC90 for each drug were obtained and compared pre-
and postincubation.
Molecular typing. Strain typing was performed on the 85 previously frozen isolates conﬁrmed to be
C. striatum. Isolates with different typing results were compared by isolate source and susceptibility
pattern. Organism DNA was extracted using the Mo Bio BiOstic bacteremia DNA isolation kit (Mo Bio,
Carlsbad, CA) and stored at 20°C prior to use. Strain typing was performed by repetitive-sequence PCR
using the primer RW3A. Analysis of PCR products was performed using the DiversiLab bacterial barcodes
system (bioMérieux, Durham, NC) (16, 37). Each unique strain type was given an alpha designation.
Statistical analysis. All data were assessed for statistical signiﬁcance using Fisher’s exact test
analysis; a P value less than 0.05 was used to establish signiﬁcance.
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